| CONTACT: Richard R. Current,
Vice President & CFO,
517/372-9200 |
Neogen reports 29%
revenue increase
LANSING, Mich., March 25, 2004 –
Neogen Corporation (Nasdaq: NEOG) today announced that its third
quarter revenues increased 29% to $14,717,000 from $11,403,000 in
the prior year. For the first nine months of Neogen’s 2004
fiscal year, revenues have increased 14% to $40,196,000 from $35,158,000
in FY 2003.
Net income for the third quarter increased
to $1,183,000 from $1,030,000 in the prior year’s comparable
quarter. Adjusted for the December 5-for-4 stock split, net income
per share was $0.14 in the third quarter compared to $0.13 for the
same period of the prior year. Year to date, net income increased
15% to $4,028,000, or to $0.48 from $0.44 on a post-split, per-share
basis.
The quarter is the 44th consecutive
profitable quarter from operations for the Company, and the 49th
quarter of the past 53 quarters to show increased revenues.
“Our solid third quarter results
are further evidence of the operational strength throughout Neogen,”
said James Herbert, Neogen’s president. “The quarter
was a combination of growth in a number of our core products, and
a great start for our recently acquired companies. We’re pleased
with the performance of both Hacco and Hess & Clark in Neogen’s
first full quarter of ownership.”
Neogen’s Animal Safety Division
led the Company’s third quarter revenue increase, with revenues
up 61% from $4,957,000 in FY 2003 to $7,976,000 in FY 2004. While
the addition of Hacco’s rodenticides and Hess & Clark’s
disinfectants accounted for the majority of the Animal Safety Division’s
revenue gain, established products showed revenue increases of 12%
in the third quarter. Sales of Neogen’s vaccine for equine
botulism and AmVet veterinary pharmaceuticals experienced strong
increases as they continued to gain market acceptance. Neogen’s
veterinary instrument sales have been bolstered by continuing improvement
in sales to veterinary retailers, including Tractor Supply Company,
Orscheln’s, and Petsmart.
In the quarter, Neogen’s Food
Safety Division again beat last year’s strong sales performance.
The division recorded a 5% increase in the third quarter as compared
to FY 2003, when the division recorded an overall 30% increase.
Food Safety Division revenue increases were led by sales of test
kits to detect genetically-modified organisms, food allergens, and
Listeria. In the third quarter, Neogen shipped a substantial order
of test kits to Brazil to detect soybeans that have been genetically
modified to make them tolerant to Roundup® herbicides. Brazil
is a leading exporter of soybeans to the European market, which
demands assurances that the commodity is GMO-free.
“We are pleased to report that
we were able to better last year’s outstanding revenue performance
in the third quarter, and we believe we can achieve greater sales
growth in future quarters,” said Lon Bohannon, Neogen’s
chief operating officer. “Sales increases in certain Food
Safety products, such as food allergen and GMO test kits, were up
significantly during the quarter, and we are excited about additional
growth opportunities for our Food Safety Division.”
Neogen’s tests to detect food
allergens continued their market growth, with sales increasing 33%
for the first nine months of the fiscal year. Proposed food allergen
labeling legislation being considered by Congress points to increased
regulatory activity on food allergens.
In March, Neogen’s board and
management took action to consolidate the Company’s Chicago
Ideal Instruments operations into existing operations in Lansing,
Mich., and Lexington, Ky. The consolidation is expected to be completed
prior to Neogen’s year end on May 31. Ideal’s inventories
of finished goods, packaging, shipping, and customer service will
be relocated to Neogen’s Lexington operations. Ideal’s
engineering, manufacturing, and quality control operations will
be transferred to the Company’s Lansing facilities.
“Obviously, consolidating operations
is an extremely difficult decision,” said Richard Current,
Neogen’s chief financial officer. “But, the move will
greatly improve logistics, reduce costs, and provide us with an
even firmer financial footing as we move forward. The states of
Michigan and Kentucky have been very helpful in providing economic
incentives to assist us streamline our current operations and accommodate
future growth.”
Neogen is expected to incur a onetime
charge to operations of $0.03 to $0.05 per share in the fourth quarter
related to the consolidation of Ideal operations. Going forward,
the Company expects to realize savings of $0.04 to $0.06 per share
per year as a result of the consolidation.
In December, Neogen announced that
its Board of Directors approved a 5-for-4 stock split. With the
split, shareholders of record on Dec. 22, 2003, received one additional
share of stock for each four shares held. The stock split was effected
in the form of a stock dividend that was paid in newly issued common
stock on Dec. 31, 2003. As of Dec. 15, 2003, Neogen had 6,400,000
shares of common stock outstanding. After the stock split, the Company
had 8,000,000 shares of common stock outstanding.
Neogen Corporation develops
and markets products dedicated to food and animal safety. The Company’s
Food Safety Division markets dehydrated culture media, and diagnostic
test kits to detect foodborne bacteria, natural toxins, genetic
modifications, food allergens, drug residues, plant diseases and
sanitation concerns. Neogen’s Animal Safety Division markets
a complete line of diagnostics, veterinary instruments, veterinary
pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.
NEOGEN CORPORATION
UNAUDITED SUMMARIZED
CONSOLIDATED OPERATING DATA
(In thousands, except for per share)
|
|
|
|
|
|
|
|
|
|
|
| Revenue(1) |
|
|
|
|
|
| |
Food Safety |
$6,741 |
$6,446 |
$20,769 |
$19,608 |
| |
Animal Safety |
7,976 |
4,957 |
19,427 |
15,550 |
| Total revenue |
|
14,717 |
11,403 |
40,196 |
35,158 |
| Cost of sales |
|
7,791 |
5,361 |
20,007 |
16,006 |
| Gross margin |
|
6,926 |
6,042 |
20,189 |
19,152 |
| Other expenses |
|
|
|
|
|
| |
Sales & marketing |
3,001 |
2,957 |
8,727 |
8,903 |
| |
Administrative |
1,368 |
1,049 |
3,423 |
3,141 |
| |
Research & development |
792 |
621 |
2,120 |
2,118 |
| Total other expenses |
|
5,161 |
4,627 |
14,270 |
14,162 |
| Operating income |
|
1,765 |
1,415 |
5,919 |
4,990 |
| Other revenue (expense) |
|
(23) |
115 |
149 |
364 |
| Income before tax |
|
1,742 |
1,530 |
6,068 |
5,354 |
| Income tax |
|
559 |
500 |
2,040 |
1,848 |
| Net income |
|
$ 1,183 |
$ 1,030 |
$ 4,028 |
$ 3,506 |
| Net income per diluted share(2) |
|
$ 0.14 |
$ 0.13 |
$ 0.48 |
$ 0.44 |
| Other information: |
|
|
|
|
|
| |
Shares to calculate per share(2) |
8,512 |
7,983 |
8,345 |
7,960 |
| |
Depreciation & amortization |
$ 308 |
$ 320 |
$ 926 |
$ 945 |
| |
Interest expense |
32 |
- |
32 |
- |
| |
Gross margin (% of sales) |
47.1% |
53.0% |
50.2% |
54.5% |
| |
Operating income (% of sales) |
12.0% |
12.4% |
14.7% |
14.2% |
| |
Revenue increase vs. FY 2003 |
29.1% |
|
14.3% |
|
| |
Net income increase vs. FY 2003 |
14.9% |
|
14.9% |
|
(1) 2003 revenues have been revised from amounts previously
reported to conform with 2003 classifications that include shipping
charges to customers as revenues
|
|
|
|
|
(2) Reflects effect of Dec.
31, 2003, 5-for-4 stock split |
|
|
|
|
NEOGEN CORPORATION
UNAUDITED SUMMARIZED
CONSOLIDATED BALANCE SHEET DATA
(In thousands)
|
|
|
|
|
|
|
|
|
|
| Assets |
|
|
|
| Current assets |
|
|
|
Cash & investments
|
$ 1,597 |
$ 8,897 |
Accounts receivable
|
9,533 |
7,499 |
Inventory
|
12,445 |
9,840 |
| Other current assets |
2,069 |
1,735 |
| Total current assets |
|
25,644 |
27,971 |
| Property & equipment |
|
10,375 |
4,640 |
| Goodwill & other assets |
|
22,308 |
15,425 |
| Total assets |
|
$ 58,327 |
$ 48,036 |
| |
|
|
|
| Liabilities & Stockholders’ Equity |
|
|
|
| Current liabilities |
|
$ 6,333 |
$ 5,763 |
| Long-term line of credit |
|
4,600 |
- |
| Other long-term liabilities |
|
859 |
871 |
| Stockholders’ equity—shares outstanding 8,008 in Feb. & 7,750
in May(2) |
|
46,535 |
41,402 |
| Total liabilities & stockholders’ equity |
|
$ 58,327 |
$ 48,036 |
Certain portions of this news release
that do not relate to historical financial information constitute
forward-looking statements. These forward-looking statements are
subject to certain risks
and uncertainties. Actual future results and trends may differ materially
from historical results
or those expected depending on a variety of factors listed in Management's
Discussion and
Analysis of Financial Condition and Results of Operations in the
Company's most
recently filed Form 10-K.
|